Verano Holdings (VRNO) Capital Expenditures (2021 - 2026)
Verano Holdings' (VRNO) quarterly Capital Expenditures came in at $14.9 million in Q1 2026, up 7.74% year-on-year from $13.9 million in Q1 2025, and up 58.33% on a QoQ basis from $9.4 million in Q4 2025.
Verano Holdings (VRNO) Capital Expenditures (2021 - 2026) Analysis & Trends
Verano Holdings (VRNO) has 6 years of Capital Expenditures data on file, last reported at $14.9 million in Q1 2026.
- On a quarterly basis, Capital Expenditures rose 7.74% year-over-year to $14.9 million in Q1 2026; TTM through Mar 2026 was $42.3 million, a 59.02% decrease from a year earlier, with the FY2025 full-year figure at $41.2 million, down 58.38% from the prior year.
- Capital Expenditures for Q1 2026 stood at $14.9 million, up from $9.4 million in the prior quarter.
- Over the last five years, Capital Expenditures for VRNO reached as high as $106.4 million in Q3 2022 and fell as low as -$103.7 million in Q4 2022.
- Historically, Capital Expenditures has averaged $9.8 million across 5 years, with a median of $10.0 million in 2023.
- Across the five-year window, Capital Expenditures tumbled 310.31% in 2022 and jumped 468.04% in 2024, its largest moves.
- Year by year, Capital Expenditures stood at -$103.7 million in 2022, then surged by 79.19% to -$21.6 million in 2023, then jumped by 165.99% to $14.2 million in 2024, then tumbled by 33.77% to $9.4 million in 2025, then surged by 58.33% to $14.9 million in 2026.
- Per Business Quant data, the three most recent Capital Expenditures figures were $14.9 million in Q1 2026, $9.4 million in Q4 2025, and $7.5 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 168.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 110.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 1.95 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 99.60 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 39.90 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 1.40 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 51.00 Mn |
| 10 | Verano Holdings | 2.02 Bn | 1.94 Bn | 98.98 Mn | 14.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 14.94 Mn |
| Mar 31, 2026 | 14.94 Mn |
| Dec 31, 2025 | 9.43 Mn |
| Dec 31, 2025 | 9.43 Mn |
| Sep 30, 2025 | 7.46 Mn |
| Sep 30, 2025 | 7.46 Mn |
| Jun 30, 2025 | 10.47 Mn |
| Jun 30, 2025 | 10.47 Mn |
| Mar 31, 2025 | 13.86 Mn |
| Mar 31, 2025 | 13.86 Mn |
| Dec 31, 2024 | 14.25 Mn |
| Dec 31, 2024 | 14.25 Mn |
| Sep 30, 2024 | 56.59 Mn |
| Sep 30, 2024 | 56.59 Mn |
| Jun 30, 2024 | 18.52 Mn |
| Jun 30, 2024 | 18.52 Mn |
| Mar 31, 2024 | 9.70 Mn |
| Mar 31, 2024 | 9.70 Mn |
| Dec 31, 2023 | -21.59 Mn |
| Dec 31, 2023 | -21.59 Mn |